Gilead Collaborates with Generics Makers to Supply Remdesivir in 127 Countries
Shots: Shots:
- Gilead has signed non-exclusive voluntary licensing agreements with Cipla, Ferozsons, Hetero, Jubilant Lifesciences and Mylan to manufacture remdesivir for distribution in 127 countries
- Gilead will share its manufacturing know-how with the five companies to ramp up remdesivir production with each company will be allowed to set the price for its generic version of the drug
- The licensees will not pay royalties to Gilead until the WHO declares the end of the Public Health Emergency of International Concern regarding COVID-19, or until a pharmaceutical product other than remdesivir or a vaccine is approved to treat COVID-19
Click here to read full press release/ article | Ref: Gilead | Image: PMLive
Related News: Gilead’s Veklury (remdesivir) Receives MHLW’s Approval for Patients with Severe COVID-19 in Japan